The PennZone

  • Home
  • Non-profit
  • Technology
  • Education
  • Business
  • Construction
  • Entertainment
  • Health
  • Software

Franklin Biolabs Names Dr. Vatsala Naageshwaran as CEO
The PennZone/10289596

Trending...
  • Creative Investment Research Analysis Finds Slower GDP Growth, Rising Inflation
  • Christian Apocalyptic Thriller Explores Biblical Prophecy, Global Technology, & the Rise of the Ant
  • Tru by Hilton El Paso Airport Opens to Guests
PHILADELPHIA, Dec. 4, 2024 ~ Franklin Biolabs, a newly established contract research organization (CRO) focused on genetic medicines, has announced the appointment of Vatsala Naageshwaran, PhD, as its Chief Executive Officer. The company was founded by renowned gene therapy pioneer, James Wilson, MD, PhD.

Dr. Naageshwaran brings over 20 years of experience in the biopharmaceutical industry to her new role at Franklin Biolabs. She is a highly accomplished executive with a strong commitment to advancing advanced therapies for patients. Throughout her career, she has successfully led cross-functional teams and delivered significant revenues to support business growth.

"We are thrilled to have Vatsala join our team at Franklin Biolabs," said Dr. Wilson, Chairperson of the company. "Her exceptional combination of business acumen and technical scientific expertise will be invaluable as we continue to grow and bring transformative therapies to patients with rare and debilitating diseases."

More on The PennZone
  • AI Is Making It Easier for API-First Platforms to Connect, Partner, Reach Customers, and Grow Revenue Faster
  • 2026 Editorial Freelancers Association Conference Focuses on Building Sustainable Careers
  • Eichelberger Performing Arts Center Announces Fall 2026 Performance Lineup
  • netElastic Powers LigaT's High-Performance Broadband Expansion and IPv6 Modernization in Portugal
  • IWS Press Expands Best-Selling Classic Wealth Library with Seventh Book

Prior to joining Franklin Biolabs, Dr. Naageshwaran held various leadership positions at biotech companies such as Myriad Genetics and Astex Pharmaceuticals. She also served as the Chief Business Officer at Absorption Systems, a contract research organization based in Exton, PA. In this role, she was responsible for driving the global business strategy for integrated services supporting small molecules, medical devices, and cell and gene therapies.

Most recently, Dr. Naageshwaran was the Vice President and Head of Business Development for US CGT & Lab Services at Pharmaron – a global service provider supporting large pharmaceutical and biotech companies in developing cell and gene therapy products.

"I am honored to join Franklin Biolabs and be a part of their groundbreaking work in gene therapy and healthcare innovation," said Dr. Naageshwaran. "I am confident that my experience will contribute to the development of innovative therapeutics that will have a profound impact on patients' lives worldwide."

More on The PennZone
  • Raiku launches rkuSOL with Sanctum, Kamino, Loopscale and Exponent
  • Greenland Mines Ltd (N A S D A Q: GRML) Advances Strategic Growth Initiatives as Critical Minerals Demand Accelerates
  • Entering the $69 Billion Animal Health Market, Delivering Record Growth, AI-Driven Healthcare Innovation, and Targeting $200 Million Revenue by 2029
  • $97.9 Million Q1 Revenue Growth Reinforces Transformation Into a Global AI & Digital Services Powerhouse: IQSTEL, Inc. (N A S D A Q: IQST)
  • Philadelphia Scientist Roohid Parast Applies Evidence-Based Research to Elite Personal Fitness

Dr. Naageshwaran holds degrees in biochemistry and molecular biology from Mount Holyoke College and pharmacometrics from the University of Maryland, Baltimore. She also completed her doctoral work in pharmaceutical drug research through a joint program between the University of Helsinki and Eastern Finland.

Her expertise has been recognized by the FDA, as she has received IDIQ and BAA grants to study PK/PD of complex products. Under her leadership, Pharmaron's San Diego site was named a Top CRO from 2018-2021. In 2021, she was nominated for the San Diego Business Woman of the Year Award. Dr. Naageshwaran's research has been presented at national conferences such as Association for Research in Vision and Ophthalmology (ARVO), American Association of Pharmaceutical Scientists (AAPS), Science of Toxicology (SOT), and American Association for Cancer Research (AACR). She has also authored multiple publications submitted to peer-reviewed journals.

With Dr. Naageshwaran at the helm, Franklin Biolabs is poised to make significant strides in advancing genetic medicines and improving patient outcomes. Her leadership and expertise will undoubtedly play a crucial role in the company's success as it continues to bring innovative therapies to those in need.
Filed Under: Business

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Community, Conservation & Waterwise Inspiration Bloom on June 6
  • Industrial and systems engineers celebrate key leaders in the field at IISE Annual Conference
  • Cosanostra Miami Rises as the Best Latin Nightclub in Miami in Under Two Years From its Opening
  • CCHR Leader's 50-Year Fight for Psychiatric Drug Victims Gains National Momentum
  • Endless Mountain Music Festival Celebrates 21st Season with America250-Inspired Lineup
  • Author Releases 7-Day Screen Time Reset for Families as Teachers Worldwide Report Children "Struggling to Grasp Basic Concepts"
  • Men's Health Month Begins with Record Proclamations, AP News Coverage, & National Momentum for Men's Health
  • Blueshirt Media Launches HIPAA-Compliant AI Call Answering for Addiction Treatment Centers
  • AdvisorVault Adds Social Media Archiving to its Consolidated D3P Service
  • UK Financial Ltd Audits Full Ethereum Architecture Verifies Corporate Wallets and 19-Token Ecosystem Ahead of CoinMarketCap Filing for Global Ranking
  • Creative Investment Research Analysis Finds Slower GDP Growth, Rising Inflation
  • TechHouse Earns Highly Selective Microsoft Support Badge
  • J&J Exterminating Celebrates 65th Anniversary and Unveils Strategic Vision at Annual Team Meeting
  • Tru by Hilton El Paso Airport Opens to Guests
  • Zenylitics Announces Leadership Transition to Continue Accelerated Growth
  • Wellness Technology Distributor Helping People Set Up Wellness Center Businesses
  • Christian Apocalyptic Thriller Explores Biblical Prophecy, Global Technology, & the Rise of the Ant
  • Turnstone Creative Expands Leadership Team with Addition of Marketing Manager
  • The Hidden Price Of Lost Property In UK Schools
  • Milton Collier, CEO & President of Freight Broker 911, Eliminates the #1 Barrier to Entry in Logistics: Announces 100% Free Freight Broker Training

Popular on PennZone

  • People & Stories/Gente y Cuentos Welcomes Two New Trustees as Organization Enters 54th Year and Expands Community Reach
  • Assymetrix Launches the Deepest Independent Prediction Market Data API
  • Resident Inspect Joins Property Meld Nexus Network with API Integration
  • RAS AP Consulting Advances to RFP Stage in Heidelberg Materials' SAP Vendor & Customer Master Data Modernization Initiative
  • New Home of the Month: Spacious Luxury Meets Modern Design in The Bristol at Heritage at Manalapan
  • Expert E-Bike Safety Advocate Issues Urgent Warning Following Recent Southern California Fatalities
  • CCHR: 'Plant-Based' Psychedelics Push Masks Synthetic Drugs and Billion-Dollar Profits
  • Veikkaus Appoints New CFO as Finland's Gambling Monopoly Braces for Breakup
  • Umbrella Becomes First FinOps Platform to Support AWS Billing Transfer Onboarding
  • BTR: i2 Group Launches i2 Amplify, a Community Platform for Intelligence Professionals Worldwide

Similar on PennZone

  • AI Is Making It Easier for API-First Platforms to Connect, Partner, Reach Customers, and Grow Revenue Faster
  • 2026 Editorial Freelancers Association Conference Focuses on Building Sustainable Careers
  • Greenland Mines Ltd (N A S D A Q: GRML) Advances Strategic Growth Initiatives as Critical Minerals Demand Accelerates
  • Entering the $69 Billion Animal Health Market, Delivering Record Growth, AI-Driven Healthcare Innovation, and Targeting $200 Million Revenue by 2029
  • $97.9 Million Q1 Revenue Growth Reinforces Transformation Into a Global AI & Digital Services Powerhouse: IQSTEL, Inc. (N A S D A Q: IQST)
  • Boston Industrial Solutions Launches Natron® 348 UV Inkjet Ink for Epson S3200 Print Heads
  • ENTOUCH Recognized on Inc.'s 2026 Best Workplaces List for the Third Year Running
  • Revenue Optics Expands Its Private Equity Practice as Sponsors Move Inside Sales to the Center of Distribution Value Creation
  • Lineus Medical Completes Financial Restructuring with KMF Investments- Launching a New Era for SafeBreak
  • AdvisorVault Adds Social Media Archiving to its Consolidated D3P Service
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us